Hulio (Adalimumab)

Hulio is indicated for the treatment of several immune‑mediated inflammatory diseases.

• Rheumatoid arthritis – moderate to severe disease in adults.
• Psoriatic arthritis – active disease refractory to conventional therapy.
• Ankylosing spondylitis – active axial disease.
• Crohn's disease – moderate to severe disease.
• Ulcerative colitis – moderate to severe disease.
• Plaque psoriasis – extensive disease not controlled by topical agents.

• Adalimumab is a fully human IgG1 monoclonal antibody that selectively binds soluble and membrane‑bound tumor necrosis factor‑alpha (TNF‑α). By attaching to TNF‑α, it prevents the cytokine from interacting with TNF receptors on cell surfaces, thereby inhibiting the downstream NF‑κB signaling cascade that drives inflammatory gene expression. This blockade reduces the recruitment and activation of immune cells that contribute to chronic inflammation in target tissues.

Adalimumab may cause a range of adverse reactions, most of which are mild and reversible, while some can be serious and require medical attention.

Common

• Injection‑site pain, redness, or swelling.
• Upper respiratory tract infections such as mild sinusitis or bronchitis.
• Headache, often transient.

Serious

• Severe infections, including tuberculosis, bacterial, or fungal infections.
• Malignancies such as lymphoma or other rare cancers.
• Demyelinating disorders of the central nervous system.

Before initiating Hulio, several safety considerations should be addressed.

• Screen for latent tuberculosis and treat if positive.
• Evaluate for active infections; do not start therapy during serious infection.
• Monitor for signs of heart failure and use cautiously in patients with moderate to severe cardiac disease.
• Assess hepatitis B status and monitor liver function during treatment.
• Pregnancy category is unknown; discuss risks and benefits with a healthcare professional.
• Vaccinate according to guidelines before starting therapy, avoiding live vaccines while on treatment.
• Regularly monitor complete blood counts and inflammatory markers as clinically indicated.

Hulio can interact with other medicines and biologics, influencing safety and efficacy.

Avoid

• Live vaccines (e.g., measles, varicella) while receiving Hulio.
• Concurrent use of another TNF inhibitor or biologic agent.
• Initiation of Hulio in the presence of an active, uncontrolled infection.

Use with caution

• Immunosuppressants such as methotrexate, azathioprine, or cyclosporine.
• Inactivated vaccines; timing may need adjustment.
• Anticoagulants (e.g., warfarin) due to potential for altered bleeding risk.
• Other agents that increase infection risk, including high‑dose corticosteroids.